We could see key trial results or FDA approvals in the months ahead…
Four Stocks for Value and Growth in an Overvalued Market
by •
Two of these companies are well-managed, have solid balance sheets, are reasonably valued and pay over 6% dividend payouts…
These 3 Growth Stocks Could Do Well for the Rest of 2017
by •
One is up some 60% since I first positively profiled it in December, living up so far to its “Home Run” potential…
Warning: Avoid This Stock at All Costs
by •
Investing in it is dangerous…
3 Small Biotech Moonshots to Add to Your Portfolio
by •
With the entire sector gaining steam, there’s still plenty of upside left…
I’ve Recently Bought More Shares of These Stocks
by •
Not only are the companies well-managed, reasonably valued, and paying substantial dividends, but they’ve also seen insider buying in their shares recently…
3 Promising Biotech Rocket Stocks to Add to Your Portfolio
by •
All three have had very positive news come out recently and have seen their stock prices start to rise. With the sector starting to wake back up, these stocks can run much, much higher…
These Types of Stocks Are Becoming Bargains
by •
They’re overlooked investment opportunities in humanity’s most important resource…
Two Cash-Cow Tech Stocks to Buy Over the Snap IPO
by •
In short, these stocks offer investors a much better value…
3 Attractive Growth Stocks with Near-Term Catalysts
by •
I’ve recently added to my position in each of these names…
